20B Stock Overview
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Biomark Diagnostics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.17 |
| 52 Week High | €0.25 |
| 52 Week Low | €0.10 |
| Beta | -0.13 |
| 1 Month Change | -5.41% |
| 3 Month Change | 4.79% |
| 1 Year Change | 19.05% |
| 3 Year Change | -50.28% |
| 5 Year Change | 250.00% |
| Change since IPO | -73.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 20B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.1% | -5.1% | -2.0% |
| 1Y | 19.0% | -21.1% | -0.3% |
Return vs Industry: 20B exceeded the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: 20B exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| 20B volatility | |
|---|---|
| 20B Average Weekly Movement | 15.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 20B has not had significant price volatility in the past 3 months.
Volatility Over Time: 20B's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Rashid Ahmed Bux | www.biomarkdiagnostics.com |
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It holds an agreement with National Research Council of Canada Industrial Research Assistance Program to support research and development of liquid biopsy assay for the early detection and screening of lung cancer; and strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts. The company was incorporated in 2014 and is headquartered in Richmond, Canada.
Biomark Diagnostics Inc. Fundamentals Summary
| 20B fundamental statistics | |
|---|---|
| Market cap | €16.45m |
| Earnings (TTM) | -€1.05m |
| Revenue (TTM) | €111.58k |
142.5x
P/S Ratio-15.1x
P/E RatioIs 20B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 20B income statement (TTM) | |
|---|---|
| Revenue | CA$163.16k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$163.16k |
| Other Expenses | CA$1.70m |
| Earnings | -CA$1.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 100.00% |
| Net Profit Margin | -942.37% |
| Debt/Equity Ratio | -166.4% |
How did 20B perform over the long term?
See historical performance and comparison